Treace Medical Concepts Enters New Agreements, Terminates Others

TL;DR

Treace Medical Concepts is restructuring its agreements, creating new debt and off-balance sheet obligations.

AI Summary

On December 16, 2025, Treace Medical Concepts, Inc. entered into a material definitive agreement and terminated another. The company also created a direct financial obligation and an obligation under an off-balance sheet arrangement. These events are considered material modifications to the rights of security holders and are subject to Regulation FD disclosure.

Why It Matters

This filing indicates significant changes in Treace Medical Concepts' contractual obligations and financial arrangements, which could impact its financial health and operational strategy.

Risk Assessment

Risk Level: medium — The creation of new financial obligations and termination of existing agreements suggests potential financial restructuring or strategic shifts that carry inherent risks.

Key Players & Entities

• TREACE MEDICAL CONCEPTS, INC. (company) — Registrant
• December 16, 2025 (date) — Date of earliest event reported

FAQ

From the Filing

0001193125-25-323802.txt : 20251218 0001193125-25-323802.hdr.sgml : 20251218 20251218084409 ACCESSION NUMBER: 0001193125-25-323802 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251216 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251218 DATE AS OF CHANGE: 20251218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TREACE MEDICAL CONCEPTS, INC. CENTRAL INDEX KEY: 0001630627 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 471052611 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40355 FILM NUMBER: 251581407 BUSINESS ADDRESS: STREET 1: 100 PALMETTO PARK PLACE CITY: PONTE VEDRA STATE: FL ZIP: 32081 BUSINESS PHONE: (904) 373-5940 MAIL ADDRESS: STREET 1: 100 PALMETTO PARK PLACE CITY: PONTE VEDRA STATE: FL ZIP: 32081 8-K 1 tmci-20251216.htm 8-K 8-K 0001630627 false 0001630627 2025-12-16 2025-12-16   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter)           Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)   100 Palmetto Park Place Ponte Vedra , Florida 32081 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: ( 904 ) 373-5940 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:           Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share TMCI The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 1.01 Entry into a Material Definitive Agreement On December 17, 2025, Treace Medical Concepts, Inc. (the “Company”) entered into (1) a Loan and Security Agreement (the “Term Loan Agreement”) with SLR Investment Corp. (“SLR”) and the lenders thereto, and (2) a Credit Agreement (the “Revolving Loan Agreement” and collectively with the Term Loan Agreement, the “Loan Agreements”) with Gemino